AstraZeneca Selects Reify Health’s StudyTeam for Breast Cancer Trial Pipeline
Published on:
Reify Health has announced that AstraZeneca has selected StudyTeam, a patient enrollment management platform, for clinical development across its breast cancer investigational therapy portfolio. Reify Health’s cloud-based solutions connect and empower the clinical trial ecosystem, starting with effective patient recruitment and enrollment. With its use of StudyTeam, AstraZeneca reinforces its reputation as a global sponsor of choice at breast cancer research sites.
AstraZeneca will expand use of the StudyTeam platform, including deployment of the Smart Patient Discovery feature. Information from a sponsor’s protocol can now be used to suggest potential patients to any research site coordinator using the StudyTeam system.
